The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression.

Borran M, Dashti-Khavidaki S, Khalili H. Expert Opin Pharmacother. 2021;22(9):1179-1192.

Trauma-informed HIV care interventions: towards a holistic approach.

Brown M, Adeagbo O. Curr HIV/AIDS Rep. 2022;19(3):177-183.

Interventions and approaches to integrating HIV and mental health services: a systematic review.

Chuah FLH, Haldane VE, Cervero-Liceras F, et al. Health Policy Plan. 2017;32(suppl 4):iv27-iv47.

Improving care outcomes for PLWH experiencing homelessness and unstable housing: a synthetic review of clinic-based strategies.

Clemenzi-Allen AA, Hickey M, Conte M, et al. Curr HIV/AIDS Rep. 2020;17(3):259-267.

Mapping the effectiveness of integrating mental health in HIV programs: a scoping review.

Conteh NK, Latona A, Mahomed O. BMC Health Serv Res. 2023;23(1):396.

The Max Clinic: medical care designed to engage the hardest-to-reach persons living with HIV in Seattle and King County, Washington.

Dombrowski JC, Ramchandani M, Dhanireddy S, et al. AIDS Patient Care STDS. 2018;32(4):149-156.

Implementation of low-barrier human immunodeficiency virus care: lessons learned from the Max Clinic in Seattle.

Dombrowski JC, Ramchandani MS, Golden MR. Clin Infect Dis. 2023;77(2):252-257.

Coordinating systems of care for HIV and opioid use disorder: a systematic review of enablers and barriers to integrated service access, and systems and tools required for implementation.

Duffy M, Ghosh A, Geltman A, et al. Med Care Res Rev. 2022;79(5):618-639.

Integrating mental health and substance use treatment with HIV care for people experiencing homelessness.

Garcia CM, Kushel MB. Lancet Psychiatry. 2022;9(8):606-608.

The prevalence and negative impacts of substance use disorders among people with HIV in the United States: a real-time delphi survey of key stakeholders.

Garner BR, Gotham HJ, Knudsen HK, et al. AIDS Behav. 2022;26(4):1183-1196.

Trauma informed interventions: a systematic review.

Han HR, Miller HN, Nkimbeng M, et al. PLoS One. 2021;16(6):e0252747.

48-week viral suppression rates in people with HIV starting long-acting CAB/RPV with initial viremia.

Hickey MD, Gistand N, Grochowski J, et al. Clin Infect Dis. 2025;80(4):864-870.

HIV treatment outcomes in POP-UP: drop-in HIV primary care model for people experiencing homelessness.

Hickey MD, Imbert E, Appa A, et al. J Infect Dis. 2022;226(suppl 3):S353-S362.

Implementation of injectable cabotegravir/rilpivirine for treatment of human immunodeficiency virus in patients with substance use disorders at a syringe exchange clinic.

Perez A, Nieves S, Meisner J. Open Forum Infect Dis. 2024;11(11):ofae640.

Long-acting injectable CAB/RPV is superior to oral ART in PWH with adherence challenges: ACTG A5359.

Rana AI, Bao Y, Zheng L, et al. Presented at: CROI; March 3-6, 2024; Denver, CO. Abstract 212.